Evidence map›Paper›PMID 28124526›Full record

ArticleInternational braz j urol : official journal of the Brazilian Society of Urology

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.

I Vukovic, D Djordjevic, N Bojanic, U Babic, I Soldatovic

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. [Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

I VukovicClinic of Urology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Serbia.
D DjordjevicClinic of Urology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Serbia.
N BojanicClinic of Urology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Serbia.
U BabicClinic of Urology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Serbia.
I SoldatovicInstitute of Medical Statistics and Informatics, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo assess predictive value of new tumor markers, precursor of prostate specific antigen (p2PSA) and its derivates-%p2PSA and prostate health index (PHI) in detection of patients with indolent and aggressive prostate cancer (PC) in a subcohort of man whose total PSA ranged from 2 to 10ng/mL. MATERIALS AND

methodsThis cross-sectional study included 129 consecutive male patients aged over 50 years, with no previous history of PC and with normal digital rectal examination findings, but with serum PSA in interval between 2 and 10ng/mL. All patients underwent standard transrectal ultrasonography guided prostate biopsy for the first time. For all patients, serum PSA, free PSA (fPSA) and p2PSA were measured and PHI and %p2PSA were calculated.

resultsPHI and %p2PSA levels were significanlty higher in patients with PC compared to those without this malignancy. The same findings have been observed in group of patients with Gleason score ≥7 compared to those with Gleason score <7. ROC analysis reveled the highest area under the curve with these two markers. Multivariate logistic regression showed significant improvement in PC detection and its agressive form (assumed as Gleason score ≥7).

conclusionsNew markers, derivates of p2PSA (especially %p2PSA and PHI), represente potentially very important clinical tool for predicting presence of PC, and even more important, to discriminate patients with Gleason score <7 from those with Gleason score ≥7 with total PSA in range from 2 to 10ng/mL.

Indexed as

AgedBiopsyCross-Sectional StudiesHumansLogistic ModelsMaleMiddle AgedNeoplasm GradingPredictive Value of TestsProstateProstate-Specific AntigenProstatic NeoplasmsProtein PrecursorsReference ValuesReproducibility of ResultsROC Curve(-2)pro-prostate-specific antigen, humanProstate-Specific AntigenProtein PrecursorsBiomarkersProstate-Specific AntigenProstatic Neoplasms

Identifiers

PMID28124526
PMCPMC5293383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.